Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus aspirin for thromboprophylaxis after the Fontan procedure in children
NL-OMON46927Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban and aspirin in Cardiovascular Malformation (CVM) (3 arms), sponsored by Janssen Pharmaceutical. Started Oct 2018; status: completed.
02
Drugs
rivaroxabanaspirin
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on NL-OMON46927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46927.